Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an update.
Australian Clinical Labs has announced the immediate resignation of non-executive director Grant Jeffery, who joined the board on 1 February 2025. The company has expressed its appreciation for Jeffery’s contributions during his tenure, and the departure prompts an adjustment to the board’s composition, though no replacement or strategic changes were disclosed in the announcement.
The change in board membership may draw investor attention to ACL’s governance and succession planning, particularly given the relatively short period Jeffery served as a director. Stakeholders will be watching for any further board changes or updates that might signal shifts in the company’s oversight, strategic direction, or approach to its diagnostics operations.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited is an Australian pathology and diagnostic services provider listed on the ASX under the ticker ACL. The company operates clinical laboratories and offers a range of medical testing services to healthcare providers and patients across Australia, positioning it as a key player in the country’s healthcare diagnostics sector.
Average Trading Volume: 792,184
Technical Sentiment Signal: Sell
Current Market Cap: A$383.9M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.